How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis

Surgery

Volumn 144, Issue 2, 2008, Pages 290-298

  Zanocco, Kyle ^a   Sturgeon, Cord ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET;

AGE DETERMINATION; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; LIFE EXPECTANCY; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

AGE FACTORS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; LIFE EXPECTANCY; MIDDLE AGED; MONTE CARLO METHOD; PARATHYROIDECTOMY; QUALITY-ADJUSTED LIFE YEARS; RECURRENT LARYNGEAL NERVE;

EID: 47549087695     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.03.044     Document Type: Article

References (25)

1. Eigelberger M.S., Cheah W.K., Ituarte P.H., Streja L., Duh Q.Y., and Clark O.H. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited?. Ann Surg 239 (2004) 528-535
2. Bilezikian J.P., Potts Jr. J.T., Fuleihan Gel H., Kleerekoper M., Neer R., Peacock M., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87 (2002) 5353-5361
3. Silverberg S.J., Brown I., and Bilezikian J.P. Age as a criterion for surgery in primary hyperparathyroidism. Am J Med 113 (2002) 681-684
4. Grant C.S., Thompson G., Farley D., and van Heerden J. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience. Arch Surg 140 (2005) 472-478
5. Pellitteri P.K. Directed parathyroid exploration: evolution and evaluation of this approach in a single-institution review of 346 patients. Laryngoscope 113 (2003) 1857-1869
6. Rao D.S., Phillips E.R., Divine G.W., and Talpos G.B. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89 (2004) 5415-5422
7. Sywak M.S., Knowlton S.T., Pasieka J.L., Parsons L.L., and Jones J. Do the National Institutes of Health consensus guidelines for parathyroidectomy predict symptom severity and surgical outcome in patients with primary hyperparathyroidism?. Surgery 132 (2002) 1013-1019
8. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 235 (2002) 665-670
9. Sejean K., Calmus S., Durand-Zaleski I., Bonnichon P., Thomopoulos P., Cormier C., et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. Eur J Endocrinol 153 (2005) 915-927
10. Zanocco K., Angelos P., and Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 140 (2006) 874-881
11. Gold M.R. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
12. Muennig P., and Khan K. Designing and conducting cost-effectiveness analyses in medicine and health care (2002), Jossey-Bass, San Francisco
13. Red book (2005), Thomson Healthcare, Montvale, NJ
14. Petitti D.B. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. 2nd ed. (2000), Oxford University Press, New York
15. Burney R.E., Jones K.R., Christy B., and Thompson N.W. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 125 (1999) 608-614
16. Sheldon D.G., Lee F.T., Neil N.J., and Ryan Jr. J.A. Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg 137 (2002) 1022-1026
17. Spector B.C., Netterville J.L., Billante C., Clary J., Reinisch L., and Smith T.L. Quality-of-life assessment in patients with unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 125 (2001) 176-182
18. Vidal-Trecan G.M., Stahl J.E., and Eckman M.H. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid 14 (2004) 933-945
19. Nichol M.B., Sengupta N., and Globe D.R. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 21 (2001) 105-112
20. Silverberg S.J., Shane E., Jacobs T.P., Siris E., and Bilezikian J.P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341 (1999) 1249-1255
21. Carneiro D.M., Solorzano C.C., and Irvin III G.L. Recurrent disease after limited parathyroidectomy for sporadic primary hyperparathyroidism. J Am Coll Surg 199 (2004) 849-853
22. Hedback G., and Oden A. Persistent disease after surgery for primary hyperparathyroidism: the long-term outcome. Eur J Endocrinol 150 (2004) 19-25
23. al-Fehaily M., and Clark O.H. Persistent or recurrent primary hyperparathyroidism. Ann Ital Chir 74 (2003) 423-434
24. Fahy B.N., Bold R.J., Beckett L., and Schneider P.D. Modern parathyroid surgery: a cost-benefit analysis of localizing strategies. Arch Surg 137 (2002) 917-922
25. Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., and Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90 (2005) 135-141